TruSight™ Hereditary Cancer Panel

NGS panel for hereditary cancer studies integrating the analysis of 113 clinically relevant genes with a rapid workflow and high coverage uniformity for the consistent detection of SNVs, indels, and CNVs.

Detailed Description

Operating Principle

An end-to-end solution based on hybrid capture of 113 genes (all exons covered plus ±20 bp regions) and library preparation via bead-linked transposome (eBLT) tagmentation, delivering ready-to-sequence libraries in 6.5 hours. Compatible with Illumina benchtop sequencing systems. Data processing is performed via BaseSpace™ or DRAGEN™, and features compatibility for tertiary analysis in Emedgene.

Library preparation workflow

Clinical Applications

Designed to support genetic counseling units, oncology, and oncogenetics laboratories in enhancing the diagnosis and risk stratification of patients with hereditary cancer predisposition syndromes through a comprehensive assessment of germline variants associated with these pathologies.

Genes included in key clinical guidelines

Benefits

This panel stands out as a reference solution for laboratories seeking efficiency without compromising quality: a fast, streamlined workflow takes you from sample to data in ~48 hours, with only ~2 hours of hands-on time, while excellent coverage uniformity supports the accurate detection of SNVs, indels, and CNVs.

Furthermore, its high flexibility allows easy scaling to meet different laboratory needs, enabling high-throughput clinical routines.

TruSight Hereditary Cancer Panel Table

Intended Audience / User

Laboratories and research groups studying genetic predisposition to cancer that require a multi-gene germline panel with high uniformity and scaling flexibility.

Key Features

Expert-designed coverage: 403 kb total footprint covering 113 genes (all exons ±20 bp) with 10,341 probes for curated, comprehensive content, ready for clinical performance.
Risk stratification capabilities: The panel features 125 integrated SNPs (48 for sample tracking and 77 for polygenic risk score in breast cancer).
Consistent data quality: Comprehensive and uniform coverage across 113 cancer predisposition genes (±20 bp intronic).
Analytical confidence: Reliable detection of SNVs, indels, and CNVs with high uniformity and concordance in validations against reference standards.
Flexible scalability: From 2 to 256 samples per run with an average depth of 300x (minimum 100x).
Full compatibility: Works with automation systems and all Illumina sequencing instruments.
High sample input versatility: From genomic DNA to direct blood or saliva samples using the Flex Lysis Reagent kit.

Area:

Hereditary cancer, Molecular Genetics, Targeted study of specific pathologies

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)

Homologous Recombination Solutions (HRS)

Portfolio of hybrid capture-based NGS solutions for the analysis of genes involved in homologous recombination repair (HRR) and the study of alterations associated with the homologous recombination pathway in different types of cancer. The range includes three scalable panels designed to meet different analytical needs: mini HRS, HRS and Extended HRS (ExtHRS). Detailed description Operating…
SOPHIA Genetics
Next Generation Sequencing (NGS)

Homologous Recombination Deficiency (HRD) Solution

Homologous Recombination Deficiency (HRD) Solution NGS- and low-pass whole-genome sequencing (low-pass WGS)-based solution for determining homologous recombination deficiency (HRD) status in ovarian cancer. Operating Principle This comprehensive solution, available as CE-IVD and for Research Use Only (RUO), is designed to support the determination of tumour HRD status in patients with ovarian cancer. It integrates two…
SOPHIA Genetics
Next Generation Sequencing (NGS)